Skip to Main Content

The number of people treated with approved gene therapies and gene-modified cell therapies like CAR-T cancer treatments in the United States and Europe has reached more than 4,500, according to an estimate from the Alliance for Regenerative Medicine.

The figure comes from the trade group’s 2019 annual report, released Thursday. The alliance also reported that 1,066 clinical trials for gene therapies, cell therapies, and tissue engineering products were underway at the end of 2019. Regenerative medicine trials have room for more than 60,000 patients to enroll around the world.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!